Search

Your search keyword '"Condorelli, Annalisa"' showing total 27 results
Start Over Author "Condorelli, Annalisa"
27 results on '"Condorelli, Annalisa"'

4. Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.

Author

Condorelli, Annalisa, Garibaldi, Bruno, Gagliano, Caterina, Romano, Alessandra, Del Fabro, Vittorio, Parrinello, Nunziatina Laura, Longo, Antonio, Cosentino, Sebastiano, Di Raimondo, Francesco, and Conticello, Concetta

Subjects
*CLINICAL trials, *OCULAR toxicology, *MULTIPLE myeloma, *ANTIBODY-drug conjugates, *MICROTUBULES
Abstract

Although the therapeutic landscape for multiple myeloma (MM) has expanded, the disease always tends to relapse. In an attempt to obtain deep and durable responses, each relapse requires the use of a new strategy. In recent years, new treatment options have emerged, even for heavily treated patients. Novel, well-tolerated, and highly effective therapies in the relapsed/refractory (RRMM) setting currently represent a real hope. Belantamab mafodotin (BLENREP™) is a first-in-class monoclonal antibody-drug conjugate whose target is B-cell maturation antigen conjugated to the cytotoxic microtubule inhibitor monomethyl auristatin F. Here, we present two cases of heavily pre-treated RRMM patients that were favorably treated with belantamab mafodotin, obtaining at least a partial response. Treatment was well tolerated and is ongoing. This is a rare report on real life clinical use of belantamab mafodotin outside of controlled clinical trials and provides information on efficacy and safety of this anti-myeloma new class of drugs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost

Author

Milone, Giuseppe, Conticello, Concetta, Leotta, Salvatore, Michieli, Maria Grazia, Martino, Massimo, Marco, Anna Lia Di, Spadaro, Andrea, Cupri, Alessandra, Condorelli, Annalisa, Milone, Giulio Antonio, Markovic, Uros, Sciortino, Roberta, Schininà, Giovanni, Moschetti, Gaetano, Villari, Loredana, and Saccardi, Riccardo

Published
2020
Full Text
View/download PDF

7. Monitoring oral iron therapy in children with iron deficiency anemia: an observational, prospective, multicenter study of AIEOP patients (Associazione Italiana Emato-Oncologia Pediatrica)

Author

Russo, Giovanna, Guardabasso, Vincenzo, Romano, Francesca, Corti, Paola, Samperi, Piera, Condorelli, Annalisa, Sainati, Laura, Maruzzi, Matteo, Facchini, Elena, Fasoli, Silvia, Giona, Fiorina, Caselli, Désirée, Pizzato, Cristina, Marinoni, Maddalena, Boscarol, Gianluca, Bertoni, Elisa, Casciana, Maria Luisa, Tucci, Fabio, Capolsini, Ilaria, Notarangelo, Lucia Dora, Giordano, Paola, Ramenghi, Ugo, and Colombatti, Raffaella

Published
2020
Full Text
View/download PDF

8. Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.

Author

Gurnari, Carmelo, Pascale, Maria Rosaria, Vitale, Antonio, Diral, Elisa, Tomelleri, Alessandro, Galossi, Elisa, Falconi, Giulia, Bruno, Alessandro, Crisafulli, Francesca, Frassi, Micol, Cattaneo, Chiara, Bertoli, Diego, Bernardi, Massimo, Condorelli, Annalisa, Morsia, Erika, Poloni, Antonella, Crisà, Elena, Caravelli, Daniela, Triggianese, Paola, and Brussino, Luisa

Published
2024
Full Text
View/download PDF

9. Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations

Author

Ferrari, Anna, primary, Cangini, Delia, additional, Ghelli Luserna di Rorà, Andrea, additional, Condorelli, Annalisa, additional, Pugliese, Marta, additional, Schininà, Giovanni, additional, Cosentino, Sebastiano, additional, Fonzi, Eugenio, additional, Domizio, Chiara, additional, Simonetti, Giorgia, additional, Leotta, Salvatore, additional, Milone, Giuseppe, additional, and Martinelli, Giovanni, additional

Published
2023
Full Text
View/download PDF

10. Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance.

Author

Giuffrida, Gaetano, Markovic, Uros, Condorelli, Annalisa, Duminuco, Andrea, Calafiore, Valeria, Conticello, Concetta, Romano, Alessandra, Grasso, Stephanie, Riccobene, Carla, Ragusa, Marco Tindaro Valentino, Esposito, Benedetta, Nicolosi, Daniela, Calagna, Marianna, Nardo, Antonella, Consoli, Ugo, Uccello, Giuseppina, Di Giacomo, Valeria, Neri, Santo, Cingari, Maria Rocca, and Rodà, Filippo

Subjects
GLYCOGEN storage disease type II, MONOCLONAL gammopathies, GAUCHER'S disease, DISEASE prevalence, LYSOSOMAL storage diseases, PATIENT experience, DELAYED diagnosis
Abstract

Background: Gaucher disease (GD) is a rare autosomal recessive inherited disorder caused by the lysosomal enzyme acid β‐glucosidase deficiency. Many patients experience a critical delay in the diagnosis of up to 8–10 years due to its rarity and variability in signs and symptoms, with the consultation of several specialists. Patients and Methods: This prospective observational study analyzed the prevalence of GD in 600 patients with monoclonal gammopathy of uncertain significance (MGUS) from January 2018 until February 2022. Results: The mean age of participants was 66 years, with a mean monoclonal component of 0.58 g/dL. In 433 MGUS patients with available data, anemia (hemoglobin level < 10 g/dL) was present in 31 patients (7%), and thrombocytopenia (platelet count <100.000/mm3) in 24 (5.5%). Of 600 MGUS patients tested for acid β‐glucosidase enzyme activity, 7 patients (1.2%) had activity below 2.5 nmol/h/mL. In comparison, GBA gene analysis was executed in 110 patients. It revealed 4 patients (0.7%) affected by GD (3 patients with compound heterozygous mutation and 1 with homozygous mutation), with a prevalence of 1 every 150 MGUS patients. Furthermore, 12 out of the remaining 106 evaluated patients (11%) were carriers of a single heterozygous mutation while having regular enzyme activity. Conclusions: The clinical heterogeneity of GD and frequent lack of awareness among physicians often lead to diagnostic delays and severe clinical manifestations. The role of MGUS in the presence of at least one clinical sign, such as low platelet count, organomegaly, bone pain, or bleeding tendency, could aid in initiating GD screening with DBS, thus reducing the period between symptom onset and the diagnosis of this rare disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. P778: A CARTOGRAPHY OF UBA1 GENE TESTING, EPIDEMIOLOGY AND CLINICAL‐GENOMIC CHARACTERISTICS: THE VEXAS ITALIAN EXPERIENCE.

Author

Gurnari, Carmelo, Rosaria Pascale, Maria, Vitale, Antonio, Diral, Elisa, Tomelleri, Alessandro, Galossi, Elisa, Falconi, Giulia, Bruno, Alessandro, Crisafulli, Francesca, Frassi, Micol, Cattaneo, Chiara, Bertoli, Diego, Bernardi, Massimo Stefano Luca, Condorelli, Annalisa, Morsia, Erika, Crisà, Elena, Triggianese, Paola, Borsellino, Beatrice, Brussino, Luisa, and Battipaglia, Giorgia

Published
2023
Full Text
View/download PDF

13. Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives

Author

Leotta, Salvatore, primary, Condorelli, Annalisa, additional, Sciortino, Roberta, additional, Milone, Giulio Antonio, additional, Bellofiore, Claudia, additional, Garibaldi, Bruno, additional, Schininà, Giovanni, additional, Spadaro, Andrea, additional, Cupri, Alessandra, additional, and Milone, Giuseppe, additional

Published
2022
Full Text
View/download PDF

17. Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement

Author

Condorelli, Annalisa, primary, Matteo, Cristina, additional, Leotta, Salvatore, additional, Schininà, Giovanni, additional, Sciortino, Roberta, additional, Piccolo, Gianna Maria, additional, Parrinello, Nunziatina Laura, additional, Proietto, Maria, additional, Camuglia, Maria Grazia, additional, Zucchetti, Massimo, additional, Milone, Giuseppe, additional, and Di Raimondo, Francesco, additional

Published
2021
Full Text
View/download PDF

20. Second-line therapy in paediatric warm autoimmune haemolytic anaemia. Guidelines from the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP)

Author

Ladogana, Saverio, Maruzzi, Matteo, Samperi, Piera, Condorelli, Annalisa, Casale, Maddalena, Giordano, Paola, Notarangelo, Lucia D, Farruggia, Piero, Giona, Fiorina, Nocerino, Agostino, Fasoli, Silvia, Casciana, Maria L, Miano, Maurizio, Tucci, Fabio, Casini, Tommaso, Saracco, Paola, Barcellini, Wilma, Zanella, Alberto, Perrotta, Silverio, and Russo, Giovanna

Subjects
COLD AGGLUTININ DISEASE, MYCOPHENOLATE-MOFETIL, RITUXIMAB THERAPY, ANEMIA, SPLENECTOMY, CHILDHOOD, MANAGEMENT
Published
2018

22. IPSS-M for Transplant Decision Making of Patients with Myelodysplastic Syndromes: A Retrospective Single-Center Study

Author

Condorelli, Annalisa, Salmoiraghi, Silvia, Pavoni, Chiara, Raviglione, Matteo, Civini, Alessia, Putelli, Alessandro, Frigeni, Marco, Intermesoli, Tamara, Lussana, Federico, Quaresmini, Giulia, Bellini, Marta, Finazzi, Maria Chiara, Spinelli, Orietta, and Rambaldi, Alessandro

Abstract

Background. The only curative treatment of Myelodysplastic syndromes (MDS) is represented by allogeneic hematopoietic cell transplantation (HCT). The risk scoring system conventionally used in clinical practice for transplant decision-making is IPSS-R (Greenberg PL et al, 2012), which has been shown to predict the HCT outcome(Della Porta MG et al, 2014). The recent broader application of next generation sequencing (NGS) in clinical practice provides an abundance of molecular data and poses the challenge of better prognostic stratification in MDS patients. Recently, Bernard et al(Elsa Bernard et al, 2022) developed a molecular prognostic score called IPSS-Molecular (IPSS-M) which defines six risk categories based on the patient's molecular profile combined with clinical and cytogenetic data. In the original study, only 9% of patients underwent HSCT, therefore the utility of this score in the transplant decision making needs to be explored.

Published
2023
Full Text
View/download PDF

23. SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Author

Borlenghi, Erika, Masina, Lorenzo, Frigeni, Marco, Lotesoriere, Ivana, Molteni, Alfredo, Fumagalli, Monica, Riva, Marta, Zappasodi, Patrizia, Bernardi, Massimo, Fracchiolla, Nicola, Gigli, Federica, Basilico, Claudia, Pagani, Chiara, Lussana, Federico, Perfetti, Paola, Cattaneo, Chiara, Tajana, Monica, Viola, Silvia, Martini, Gianluca, Catalano, Gloria, Sciumè, Mariarita, Condorelli, Annalisa, Cela, Giselda, Rossi, Giuseppe, Tucci, Alessandra, Cairoli, Roberto, and Todisco, Elisabetta

Abstract

Introduction:In elderly acute myeloid leukemia (AML) patients (pts) the debate about the use of intensive chemotherapy (iC) as opposed to non-intensive therapy (niT) or best supportive care (BSC) is a hot topic, particularly after the introduction of venetoclax (VEN) use. Age, comorbidities, functional impairment, therapy benefits and risks, pts preferences, and AML features influence this choice. The SIE/SIES/GITMO (“fitness”) criteria (Ferrara, 2013) are a valuable and comprehensive tool, but a revalidation is needed in the light of the new treatment options.

Published
2023
Full Text
View/download PDF

24. Stem Cell Transplantation in Acute Myeloid Laeukemia

Author

Milone, Giuseppe, Sciortino, Roberta, Cupri, Alessandra, Schininà, Giovanni, Leotta, Salvatore, and Condorelli, Annalisa

Subjects
Medical
Abstract

Allogeneic hematopoietic stem cell transplantation represents the only potentially curative therapeutic approach for Acute Myeloid Leukemia. The choice to perform an allogeneic hematopoietic transplant is the result of a decision-making process that considers disease-related factors (AML-risk category and the state of disease at the time of transplant), the type of donor available and his characteristics (HLA compatibility, gender, CMV serostatus) and the individual risk associated with the procedure itself. The choice of the appropriate conditioning regimen depends on the patient’s age and comorbidities. While the introduction of reduced intensity regimen and the availability of alternative donors allows more patients to be eligible for transplantation, myeloablative conditioning remains the standard of care for fit patients. Disease relapse is the leading cause of treatment failure and new strategies attempting at reducing the relapse incidence post transplantation are currently being investigated.

Published
2019

25. Second-line therapy in paediatric warm autoimmune haemolytic anaemia. Guidelines from the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP)

Author

Ladogana S., Maruzzi M., Samperi P., Condorelli A., Casale M., Giordano P., Notarangelo L. D., Farruggia P., Giona F., Nocerino A., Fasoli S., Casciana M. L., Miano M., Tucci F., Casini T., Saracco P., Barcellini W., Zanella A., Perrotta S., Russo G., Baronci C., Casadei A. M., Cazzaniga G., Coluzzi S., Ciliberti A., Del Vecchio G. C., Facchini E., Girelli G., Lazzareschi I., Masera N., Perseghin P., Peruccio D., Petrone A., Sau A., Schiro R., Tumino M., Vasta I., Verzegnassi F., Ladogana, Saverio, Maruzzi, Matteo, Samperi, Piera, Condorelli, Annalisa, Casale, Maddalena, Giordano, Paola, Notarangelo, Lucia D., Farruggia, Piero, Giona, Fiorina, Nocerino, Agostino, Fasoli, Silvia, Casciana, Maria L., Miano, Maurizio, Tucci, Fabio, Casini, Tommaso, Saracco, Paola, Barcellini, Wilma, Zanella, Alberto, Perrotta, Silverio, Russo, Giovanna, Baronci, Carlo, Casadei, Anna Maria, Cazzaniga, Giovanni, Coluzzi, Serelina, Corti, Paola, Del Vecchio, Giovanni C., Facchini, Elena, Girelli, Gabriella, Lazzareschi, Ilaria, Masera, Nicoletta, Perseghin, Paolo, Peruccio, Daniela, Petrone, Angelamaria, Sau, Antonella, Schirò, Raffaella, Tumino, Manuela, Vasta, Isabella, Verzegnassi, Federico, Ladogana, S, Maruzzi, M, Samperi, P, Condorelli, A, Casale, M, Giordano, P, Notarangelo, L, Farruggia, P, Giona, F, Nocerino, A, Fasoli, S, Casciana, M, Miano, M, Tucci, F, Casini, T, Saracco, P, Barcellini, W, Zanella, A, Perrotta, S, Russo, G, Baronci, C, Casadei, A, Cazzaniga, G, Coluzzi, S, Ciliberti, A, Del Vecchio, G, Facchini, E, Girelli, G, Lazzareschi, I, Masera, N, Perseghin, P, Peruccio, D, Petrone, A, Sau, A, Schiro, R, Tumino, M, Vasta, I, and Verzegnassi, F

Subjects
Male, autoimmune haemolytic anaemia, child, therapy, rituximab, mycophenolate mofetil, splenectomy, therapy, Erythrocytes, Adolescent, Incidence, mycophenolate mofetil, Infant, Hematology, Guideline, splenectomy, rituximab, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Child, Preschool, Humans, Immunology and Allergy, autoimmune haemolytic anaemia, Female, Anemia, Hemolytic, Autoimmune, Child, Autoantibodies
Published
2018

27. Second-line therapy in paediatric warm autoimmune haemolytic anaemia. Guidelines from the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP).

Author

Ladogana S, Maruzzi M, Samperi P, Condorelli A, Casale M, Giordano P, Notarangelo LD, Farruggia P, Giona F, Nocerino A, Fasoli S, Casciana ML, Miano M, Tucci F, Casini T, Saracco P, Barcellini W, Zanella A, Perrotta S, and Russo G

Subjects
Adolescent, Anemia, Hemolytic, Autoimmune blood, Anemia, Hemolytic, Autoimmune epidemiology, Child, Child, Preschool, Female, Humans, Incidence, Infant, Male, Anemia, Hemolytic, Autoimmune diagnosis, Anemia, Hemolytic, Autoimmune therapy, Autoantibodies blood, Erythrocytes metabolism
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results